Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and member of the Board. This represents an important milestone for the company which aims to benefit cancer patients through the implementation of advanced precision oncology diagnostics to improve screening and enable better treatment decisions for people affected by cancer.
Oxford Cancer Biomarkers applies molecular insights into disease and pathological processes to develop innovative oncology screening and diagnostic tests, commencing with colon cancer, a disease affecting 1.2 million patients every year, presenting a major global burden of morbidity and mortality.
“We are at a pivotal point in the growth of Oxford Cancer Biomarkers, with validated transformational technology platforms ready for global commercialisation as we accelerate our progress to become leaders in precision medicine for cancer” said Oxford Cancer Biomarkers Chairman David Oxlade. “We are delighted that David Browning will be able to apply his considerable healthcare industry knowledge and network to lead our team to enable improved cancer screening and in making precision oncology diagnostics and intervention an accessible daily reality for millions of patients. The Board would also like to thank Nick La Thangue who has held the position of CEO since November 2013 and will now resume his role as Chief Scientific Officer”.
David’s previous role was Senior Vice President of Innovation and Development of the BioCIty Group, where he led the successful launch and growth of MediCity, applying his 36 years of applied healthcare experience with a focus on technology translation and new business creation to harness scientific innovation to address global health and wellbeing challenges.
His primary experience was gained as a biomedical scientist within the UK National Health Service and implementing clinical diagnostics innovation within Amersham International and Johnson & Johnson. He has led start-ups, including Oxonica Healthcare, an Oxford University spin-out, applying nanotechnology in the development of advanced medical devices. Within Philips, David led personalised medicine and pro-active healthcare businesses with a focus on oncology.
David said “Oxford Cancer Biomarkers has developed key tools to support a step change in the screening and treatment of cancer. I look forward to leading the team and developing our partnerships to accelerate the implementation of improved standards of care and health economic outcomes in cancer medicine and in realising the maximum value for our customers and stakeholders”.
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.
For more information, please visit: http://www.oxfordcancerbiomarkers.com
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
David Browning, CEO / David Oxlade, Chairman